Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2012083092 |
Title |
Bi-Dentate Compounds As Kinase Inhibitors. |
Abstract |
The present disclosure provides compound having the general structure A or pharmaceutically acceptable salts thereof: Het-L-P (A) wherein Het is an aromatic moiety comprising a heterocyclic structure mimicking ATP, P is a docking site derived peptide or a docking site peptide rnimetic, and L is a linking moiety, wherein L links the ATP mimetic to the docking site peptide moiety. The compounds having the general structure A can serve as inhibitors of kinases, such as the kinases JNK, Erk and p38. |
Applicant(s) |
Sanford-Burnham Medical Research Institute |
Representative Drug(s) |
D0Q8CR |
Drug Info
|
IC50 = 190 nM |
Click to Show More |
[1] |
2
|
D08OJQ
|
Drug Info
|
IC50 > 5000 nM
|
[1] |
3
|
D0G7LB
|
Drug Info
|
IC50 > 10000 nM
|
[1] |
Patent ID |
WO2011071491 |
Title |
Isotopologues of 4-[9-(Tetrahydro-Furan-3-Yl)-8-(2, 4, 6- Trifluoro-Phenylamino)-9H-Purin-2-Ylamino]-Cyclohexan-1-Ol. |
Abstract |
Provided herein are isotopologues of Compound 1, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided. |
Applicant(s) |
Signal Pharmaceuticals |
Representative Drug(s) |
D06JRV |
Drug Info
|
IC50 = 3400 nM |
[1] |
Patent ID |
WO2010069833 |
Title |
Pyrimidin- 2 -Ylamino Derivatives and Their Use To Treat Inflammation. |
Abstract |
Compounds of formula (I) modulate JNK wherein X1 and X2 are each simultaneously N or CH; X3 is CH-R2 or N-SO2R, where R is lower alkyl; R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; R2 is formula (II), where R3 is H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D0H4HD |
Drug Info
|
IC50 < 10000 nM |
[1] |
Patent ID |
WO2008028860 |
Title |
Benzotriazole Kinase Modulators. |
Abstract |
The invention is concerned with novel benzotriazole derivatives of Formula (I) Wherein R, R1, R2, R3, and m are as defined in the description and the claims, as well as physiologically acceptable salts thereof. These compounds are JNK and CDK modulators. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D0H4HD |
Drug Info
|
IC50 < 10000 nM |
[1] |
Patent ID |
WO2001027268 |
Title |
Cell-Permeable Peptide Inhibitors of The Jnk Signal Transduction Pathway. |
Abstract |
The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells. |
Applicant(s) |
University of Lausanne |
Representative Drug(s) |
D03JFK |
Drug Info
|
N.A. |
[1] |